Cargando…

Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?

One of the main mechanisms carried out by the cells to counteract several forms of stress is the activation of the nuclear factor erythroid 2-related factor (Nrf2) signaling. Nrf2 signaling controls the expression of many genes through the binding of a specific cis-acting element known as the antiox...

Descripción completa

Detalles Bibliográficos
Autores principales: Pompili, Simona, Sferra, Roberta, Gaudio, Eugenio, Viscido, Angelo, Frieri, Giuseppe, Vetuschi, Antonella, Latella, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720292/
https://www.ncbi.nlm.nih.gov/pubmed/31434263
http://dx.doi.org/10.3390/ijms20164061
_version_ 1783448091710455808
author Pompili, Simona
Sferra, Roberta
Gaudio, Eugenio
Viscido, Angelo
Frieri, Giuseppe
Vetuschi, Antonella
Latella, Giovanni
author_facet Pompili, Simona
Sferra, Roberta
Gaudio, Eugenio
Viscido, Angelo
Frieri, Giuseppe
Vetuschi, Antonella
Latella, Giovanni
author_sort Pompili, Simona
collection PubMed
description One of the main mechanisms carried out by the cells to counteract several forms of stress is the activation of the nuclear factor erythroid 2-related factor (Nrf2) signaling. Nrf2 signaling controls the expression of many genes through the binding of a specific cis-acting element known as the antioxidant response element (ARE). Activation of Nrf2/ARE signaling can mitigate several pathologic mechanisms associated with an autoimmune response, digestive and metabolic disorders, as well as respiratory, cardiovascular, and neurodegenerative diseases. Indeed, several studies have demonstrated that Nrf2 pathway plays a key role in inflammation and in cancer development in many organs, including the intestine. Nrf2 appears to be involved in inflammatory bowel disease (IBD), an immune-mediated chronic and disabling disease, with a high risk of developing intestinal fibrotic strictures and cancer. Currently, drugs able to increase cytoprotective Nrf2 function are in clinical trials or already being used in clinical practice to reduce the progression of some degenerative conditions. The role of Nrf2 in cancer development and progression is controversial, and drugs able to inhibit abnormal levels of Nrf2 are also under investigation. The goal of this review is to analyze and discuss Nrf2-dependent signals in the initiation and progression of intestinal fibrosis and cancers occurring in IBD.
format Online
Article
Text
id pubmed-6720292
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67202922019-10-30 Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease? Pompili, Simona Sferra, Roberta Gaudio, Eugenio Viscido, Angelo Frieri, Giuseppe Vetuschi, Antonella Latella, Giovanni Int J Mol Sci Review One of the main mechanisms carried out by the cells to counteract several forms of stress is the activation of the nuclear factor erythroid 2-related factor (Nrf2) signaling. Nrf2 signaling controls the expression of many genes through the binding of a specific cis-acting element known as the antioxidant response element (ARE). Activation of Nrf2/ARE signaling can mitigate several pathologic mechanisms associated with an autoimmune response, digestive and metabolic disorders, as well as respiratory, cardiovascular, and neurodegenerative diseases. Indeed, several studies have demonstrated that Nrf2 pathway plays a key role in inflammation and in cancer development in many organs, including the intestine. Nrf2 appears to be involved in inflammatory bowel disease (IBD), an immune-mediated chronic and disabling disease, with a high risk of developing intestinal fibrotic strictures and cancer. Currently, drugs able to increase cytoprotective Nrf2 function are in clinical trials or already being used in clinical practice to reduce the progression of some degenerative conditions. The role of Nrf2 in cancer development and progression is controversial, and drugs able to inhibit abnormal levels of Nrf2 are also under investigation. The goal of this review is to analyze and discuss Nrf2-dependent signals in the initiation and progression of intestinal fibrosis and cancers occurring in IBD. MDPI 2019-08-20 /pmc/articles/PMC6720292/ /pubmed/31434263 http://dx.doi.org/10.3390/ijms20164061 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pompili, Simona
Sferra, Roberta
Gaudio, Eugenio
Viscido, Angelo
Frieri, Giuseppe
Vetuschi, Antonella
Latella, Giovanni
Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
title Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
title_full Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
title_fullStr Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
title_full_unstemmed Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
title_short Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?
title_sort can nrf2 modulate the development of intestinal fibrosis and cancer in inflammatory bowel disease?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720292/
https://www.ncbi.nlm.nih.gov/pubmed/31434263
http://dx.doi.org/10.3390/ijms20164061
work_keys_str_mv AT pompilisimona cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease
AT sferraroberta cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease
AT gaudioeugenio cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease
AT viscidoangelo cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease
AT frierigiuseppe cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease
AT vetuschiantonella cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease
AT latellagiovanni cannrf2modulatethedevelopmentofintestinalfibrosisandcancerininflammatoryboweldisease